Value in health regional issues最新文献

{"title":"Reviewer Acknowledgment","authors":"","doi":"10.1016/j.vhri.2025.101102","DOIUrl":"10.1016/j.vhri.2025.101102","url":null,"abstract":"","PeriodicalId":23497,"journal":{"name":"Value in health regional issues","volume":"47 ","pages":"Article 101102"},"PeriodicalIF":1.4,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143886751","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cost-Effectiveness Analysis of Inclisiran for the Treatment of Primary Hypercholesterolemia or Mixed Dyslipidemia in Singapore","authors":"Yan Ling Lim MPH ,&nbsp;Ru-San Tan MBBS ,&nbsp;Kian Keong Poh MB, BChir ,&nbsp;Xiao Jun Wang PhD","doi":"10.1016/j.vhri.2024.101067","DOIUrl":"10.1016/j.vhri.2024.101067","url":null,"abstract":"<div><h3>Objectives</h3><div>This analysis evaluated the cost-effectiveness of inclisiran plus standard of care (SoC; comprising statins, ezetimibe, and fenofibrate) in primary hypercholesterolemia or mixed dyslipidemia from a Singapore healthcare system perspective. Inclisiran + SoC was separately compared with SoC, alirocumab + SoC, and evolocumab + SoC.</div></div><div><h3>Methods</h3><div>A lifetime Markov model in the United Kingdom (UK) was adapted to the Singapore setting. The modeled population (comprising 4 separate subpopulations: “primary prevention heterozygous familial hypercholesterolemia [HeFH],” “secondary prevention HeFH,” “atherosclerotic cardiovascular disease [ASCVD],” “primary prevention with elevated risk”) and efficacy of inclisiran were informed by the ORION-9, ORION-10, and ORION-11 trials. Comparative efficacies of inclisiran versus comparators were informed by a network meta-analysis. Baseline cardiovascular event risks were obtained from a large UK real-world data set and the Netherlands, and UK-based utilities were applied. Baseline population characteristics, distribution of patients in the ASCVD subpopulation, and costs were sourced from local clinicians and published literature. A willingness-to-pay threshold of S$45 000/quality-adjusted life-year (QALY) was selected.</div></div><div><h3>Results</h3><div>Across all subpopulations, inclisiran + SoC resulted in higher QALYs and total costs than SoC (incremental cost-effectiveness ratios, S$35 658-163 896/QALY) and dominated evolocumab + SoC and alirocumab + SoC. At the selected threshold, inclisiran + SoC is cost-effective among patients with ASCVD and secondary prevention HeFH. The deterministic sensitivity analysis found that the model was most sensitive to inclisiran’s acquisition cost and efficacy and rate ratios translating reductions in low-density lipoprotein cholesterol levels to the risk of cardiovascular death.</div></div><div><h3>Conclusions</h3><div>Compared with SoC, evolocumab + SoC, and alirocumab + SoC, inclisiran + SoC is cost-effective in patients with primary hypercholesterolemia or mixed dyslipidemia in Singapore at the selected threshold.</div></div>","PeriodicalId":23497,"journal":{"name":"Value in health regional issues","volume":"47 ","pages":"Article 101067"},"PeriodicalIF":1.4,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143012493","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Diagnosing Burkitt Lymphoma in Sub-Saharan Africa by Sequencing of Circulating Tumor DNA: A Comparative Microcosting Study","authors":"Liz Morrell PhD ,&nbsp;Malale Tungu PhD ,&nbsp;Caroline Achola MMed ,&nbsp;Ismail Legason MSc ,&nbsp;Erick Magorosa MSc ,&nbsp;Priscus Mapendo PGDip ,&nbsp;Leah Mnango MMed ,&nbsp;Alex Mremi PhD ,&nbsp;Heavenlight Christopher MSc ,&nbsp;Emmanuel Josephat MSc ,&nbsp;Adam Burns PhD ,&nbsp;Helene Dreau MSc ,&nbsp;Mihaela Leonte BSc ,&nbsp;Lulu Chirande MMed ,&nbsp;Salama Mahawi MD ,&nbsp;Elifuraha Mkwizu MMed ,&nbsp;Hadija Mwamtemi PhD ,&nbsp;Godlove Sandi MD ,&nbsp;Claire El Mouden PhD ,&nbsp;Anna Schuh PhD ,&nbsp;Sarah Wordsworth","doi":"10.1016/j.vhri.2025.101113","DOIUrl":"10.1016/j.vhri.2025.101113","url":null,"abstract":"<div><h3>Objectives</h3><div>Determining the cost of diagnosis of Burkitt lymphoma by DNA sequencing from a blood sample, compared with current histopathology. Estimating future sequencing costs at increased scale and exploring the effect of positivity rate on per-case cost.</div></div><div><h3>Methods</h3><div>We conducted a microcosting of both diagnostics. Resource use information was derived from standard operating procedures and interviews with staff. Unit cost data were from salary scales, purchase records, and publicly available prices. Costs were collected during 2021 and 2022, in the currency of purchase, and converted to common year (2024) and currency (US dollar [$]), with a discount rate of 5%. For increased scale, we assumed simple scaling up of current sample preparation and higher-capacity sequencing machines running at least once a week to maintain turnaround times.</div></div><div><h3>Results</h3><div>We estimated a cost of $185.01 per patient for histopathology, with the main cost drivers being staining ($87.20, largely immunohistochemistry consumables, including $34.52 for antibodies) and the biopsy procedure ($72.29). The cost of the sequencing-based diagnostic was $710.15 at current throughput, with the largest contribution from the sequencing step because of the cost of sequencing reagents ($175.48 per sample). Costs are sensitive to throughput, reagent costs, and efficiency of utilization of equipment. At the current prevalence, cost per positive case is 2-fold higher at a positivity rate of 25% compared with 75%.</div></div><div><h3>Conclusions</h3><div>With the current technology and throughput, sequencing is likely to increase the cost of diagnosis compared with current pathology. Costs will reduce with increased scale, which requires establishing local reagent supply and maintenance capability.</div></div>","PeriodicalId":23497,"journal":{"name":"Value in health regional issues","volume":"48 ","pages":"Article 101113"},"PeriodicalIF":1.4,"publicationDate":"2025-04-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143807358","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Public Preferences for Reducing Health Inequality in Japan: A National Survey.","authors":"Kyoko Shimamoto, Tim Doran, Richard Cookson","doi":"10.1016/j.vhri.2025.101111","DOIUrl":"https://doi.org/10.1016/j.vhri.2025.101111","url":null,"abstract":"<p><strong>Objectives: </strong>Making health programs more equitable sometimes reduces their health benefit per unit of cost. Policy makers therefore need to understand public preferences for reducing health inequalities; however, this evidence has been restricted to Europe, with no estimates available in Asia. Thus, this study aimed to gauge health inequality aversion in Japan in comparison with the UK populations.</p><p><strong>Methods: </strong>National online survey of Japanese adults (aged 18-69), using a Japanese version of a UK benefit trade-off questionnaire, involving pairwise policy choices with different levels of health benefit and inequality. Attitudes toward reducing health inequality were classified using the same approach as the original UK study. Regression analyses were conducted to explore heterogeneity by age, gender, income, education, and geographic region.</p><p><strong>Results: </strong>On average, respondents in the analytic sample (n = 473) weighed health gains to the poorest fifth of people approximately 6 times more highly than health gains to the richest fifth; 76.9% had positive health inequality aversion. Health inequality aversion was higher in the poorest fifth of respondents and in the northern region of Japan, but otherwise was not closely correlated with other characteristics. There was a higher proportion of invalid responses in Japan (67.9%) than the United Kingdom (47.0%).</p><p><strong>Conclusions: </strong>Most people in Japan appear willing to forgo gains in total population health to reduce health inequality, such as in the United Kingdom. However, more research is needed to understand the high rate of inconsistent responses to the online version of this questionnaire, which was even higher in Japan than in the United Kingdom.</p>","PeriodicalId":23497,"journal":{"name":"Value in health regional issues","volume":" ","pages":"101111"},"PeriodicalIF":1.4,"publicationDate":"2025-04-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143781346","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cost-Effectiveness Analysis of Mammography-Based Breast Cancer Screening in Indonesia","authors":"Ajeng V. Icanervilia PhD ,&nbsp;Keris Poelhekken MSc ,&nbsp;Jarir At Thobari PhD ,&nbsp;Lina Choridah PhD ,&nbsp;Susanna H. Hutajulu PhD ,&nbsp;Geertruida H. de Bock PhD ,&nbsp;Maarten J. Postma PhD ,&nbsp;Marcel J.W. Greuter PhD ,&nbsp;Antoinette D.I. van Asselt PhD","doi":"10.1016/j.vhri.2025.101112","DOIUrl":"10.1016/j.vhri.2025.101112","url":null,"abstract":"<div><h3>Objectives</h3><div>The Indonesian government has not implemented mammography as national screening program. Therefore, we evaluated the cost-effectiveness of mammography-based breast cancer screening strategy in Indonesia from a societal perspective.</div></div><div><h3>Methods</h3><div>The Simulation Model on radiation Risk and breast cancer Screening was used to examine various breast cancer screening scenarios, including different screening age (40-65 vs 35-65 years), frequency (every 2, 3, 4, or 5 years), and participation rate (50%, 70%, and 100%). The model’s input parameters were independently derived from published population statistics and systematic literature.</div></div><div><h3>Results</h3><div>Our findings indicate that, across all scenarios, mammography screening was cost-effective compared with no screening under the following conditions: (1) screening women aged 40 to 65 every 4 years at 50% participation rate, (2) screening women aged 40 to 65 every 4 years at 70% participation rate, (3) screening women aged 40 to 65 every 3 years at 70% participation rate, and (4) screening women aged 40 to 65 every 2 years at 100% participation rate. The incremental cost-effectiveness ratios these scenarios compared with the next best alternative were $4758 per life year gained (US dollars/LYG), $5263/LYG, $5436/LYG, and $7569/LYG, respectively, all of which were less than 3 times Indonesia’s gross domestic product per capita.</div></div><div><h3>Conclusions</h3><div>We recommend implementing mammography screening as a national program in Indonesia. The cost-effectiveness of screening strategies depends on factors such as participation rates, screening age, frequency, and the government’s willingness-to-pay threshold. We recognize Indonesia’s competing health priorities and limited resources. Acknowledging these priorities will help policymakers in making informed decisions about resource allocation.</div></div>","PeriodicalId":23497,"journal":{"name":"Value in health regional issues","volume":"48 ","pages":"Article 101112"},"PeriodicalIF":1.4,"publicationDate":"2025-04-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143761153","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Toward Better Measurement of Financial Risk Protection in Health Expenditure: The Case of Chile","authors":"Joaquín Prieto PhD ,&nbsp;Lorena Hoffmeister PhD","doi":"10.1016/j.vhri.2025.101086","DOIUrl":"10.1016/j.vhri.2025.101086","url":null,"abstract":"<div><h3>Objectives</h3><div>Our study highlights the impact of out-of-pocket health expenditure (OOPHE) in highly unequal countries, where the middle class is particularly vulnerable to declines in well-being. We modify 2 financial protection measures—impoverishment and catastrophic health expenditure (CHE)—to address this issue. The first adjustment improves the classification of households based on their risk of poverty due to OOPHE, whereas the second corrects the underestimation of CHE for poorer households and the overestimation for the richest.</div></div><div><h3>Methods</h3><div>We applied our adjusted financial protection measures to data from the Chilean Household Budget Surveys (2006-2007, 2011-2012, 2016-2017, and 2021-2022) and compared the results with conventional CHE and impoverishment measures. Logistic regressions were used to identify factors associated with CHE.</div></div><div><h3>Results</h3><div>Our impoverishment risk indicator indicates that approximately 10% of Chilean households entered poverty, became poorer, or were at high risk due to OOPHE in 20. Our revised CHE measure suggests that approximately 15.8% of households faced financial hardship, with both figures exceeding conventional estimates. Households with more women and an older average age were more likely to experience CHE.</div></div><div><h3>Conclusions</h3><div>Effective and equitable access to health services, along with adequate financial protection, is critical to achieving universal health coverage. However, in countries with high-income inequality and a high proportion of nonpoor households close to the poverty line, conventional measures may have blind spots for monitoring and analyzing financial hardship in health spending. This research provides evidence to open the debate on this issue.</div></div>","PeriodicalId":23497,"journal":{"name":"Value in health regional issues","volume":"47 ","pages":"Article 101086"},"PeriodicalIF":1.4,"publicationDate":"2025-03-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143724893","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cost-Effectiveness of the Kidney Transplant Compared With Hemodialysis in End-Stage Renal Disease in Dubai, the United Arab Emirates: A Cost-Utility Study","authors":"Meenu Mahak Soni MBBS, MSc ,&nbsp;Heba M. Mamdouh PhD ,&nbsp;Sebastien Cochinard PhD ,&nbsp;Diego Rosselli MD, MSc","doi":"10.1016/j.vhri.2025.101109","DOIUrl":"10.1016/j.vhri.2025.101109","url":null,"abstract":"<div><h3>Objectives</h3><div>This study aims to examine the cost-effectiveness of renal transplantation and hemodialysis among patients with end-stage renal disease in Dubai, the United Arab Emirates.</div></div><div><h3>Methods</h3><div>A Markov model was developed to examine the cost-effectiveness of hemodialysis and renal transplant over a 5-year time horizon from the payer perspective, using empirical data on treatment costs from private hospitals in Dubai, utilities from Tufts Cost-Effectiveness Analysis Registry, and transition probabilities from European Renal Association-European Dialysis and Transplant Association registry data.</div></div><div><h3>Results</h3><div>In the base-case analysis, the discounted average total cost for 5 years was AED 961, 323 ($261 941) for transplantation and AED 971 538 ($264 724) for hemodialysis, with 3.4 and 2.1 quality-adjusted life years (QALY), respectively. The costs of first-year transplant and hemodialysis were AED 470 000 ($128 065) and AED 276 000 ($75 204) with 0.72 and 0.55 QALY, respectively. Transplantation became the dominant treatment strategy by the fourth year and was a cost-effective alternative from the second year on with an incremental cost-effectiveness ratio of AED 53 205 ($14 497 per QALY) (for a cost difference of AED 36 712 ($10 003) and QALY gain of 0.69).</div></div><div><h3>Conclusions</h3><div>Although the cost of the first year after transplantation was high, transplantation was more effective than hemodialysis over 2 years and was less costly over a longer period. The study suggests that performing renal transplants for patients with end-stage renal disease is more cost-effective than hemodialysis.</div></div>","PeriodicalId":23497,"journal":{"name":"Value in health regional issues","volume":"48 ","pages":"Article 101109"},"PeriodicalIF":1.4,"publicationDate":"2025-03-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143697543","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Quality of Economic Evaluations of Interventions to Improve Women and Child Health in Latin America: A Systematic Review","authors":"Youssef Al Ghouch MD, MSc ,&nbsp;María J. Mendoza-Jiménez MSc ,&nbsp;Job van Exel PhD","doi":"10.1016/j.vhri.2025.101101","DOIUrl":"10.1016/j.vhri.2025.101101","url":null,"abstract":"<div><h3>Objectives</h3><div>This study aims to characterize and assess the reporting and methodological quality of health economic evaluations (HEEs) of interventions to improve women’s and children’s health in Latin America from 2004 to 2023.</div></div><div><h3>Methods</h3><div>A systematic literature review was conducted according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines. PubMed was searched for HEEs published between 2004 and 2023. The search terms included HEEs or cost-benefit analysis, Latin America or Latin American countries, and pediatrics and/or gynecology. Articles were eligible for inclusion if they were HEEs; published in English, Spanish, or Portuguese; and focused on pediatrics and/or gynecology in Latin America. Data extraction included study characteristics, methodological aspects, reporting, and methodological quality based on the Consolidated Health Economic Evaluation Reporting Standards 2013 and Quality of Health Economic Studies checklists.</div></div><div><h3>Results</h3><div>Of 141 articles identified, 55 met the inclusion criteria. Most articles were cost-effectiveness evaluations conducted in Colombia and were aimed at pediatric patients. The quality assessment revealed that most Consolidated Health Economic Evaluation Reporting Standards and Quality of Health Economic Studies items were reported in at least 60% of the articles and that the study setting, justification for study perspective, bias acknowledgment, and subgroup analyses were the least frequently reported items.</div></div><div><h3>Conclusions</h3><div>This study highlights that although the number of HEEs in pediatrics and/or gynecology in Latin American countries is growing, to improve the transparency and generalizability of HEEs, the reporting and methodological quality of HEEs need to be improved. Seven key areas were identified for improving adherence to international quality standards.</div></div>","PeriodicalId":23497,"journal":{"name":"Value in health regional issues","volume":"48 ","pages":"Article 101101"},"PeriodicalIF":1.4,"publicationDate":"2025-03-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143696912","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Assessing Women’s Preference and Willingness to Pay for Breast Cancer Screening: A Discrete Choice Experiment Approach","authors":"Reyhane Tahal MHE ,&nbsp;Azin Nahvijou MD, PhD ,&nbsp;Ali Akbari Sari MD, PhD ,&nbsp;Rajabali Daroudi PhD","doi":"10.1016/j.vhri.2025.101110","DOIUrl":"10.1016/j.vhri.2025.101110","url":null,"abstract":"<div><h3>Objectives</h3><div>This study aimed to explore women’s preferences regarding breast cancer screening using a discrete choice experiment and willingness-to-pay analysis.</div></div><div><h3>Methods</h3><div>A discrete-choice experiment was conducted among 255 women aged 40 to 65 years who were referred to health centers in Tehran city. The experiment included attributes such as screening methods (clinical examination and mammography), number of deaths prevented, possibility of misdiagnosis and unnecessary biopsy, screening intervals, and cost of the screening test. A conditional logit model was used to estimate preferences, and willingness-to-pay values were derived from the model coefficients.</div></div><div><h3>Results</h3><div>Women revealed a strong preference for mammography over clinical examination(odds ratio [OR] 1.73; 95% CI 1.47-2.04; <em>P</em> &lt; .001). Compared with 1 death prevented per 1000 women, the ORs for 3 and 6 deaths prevented per 1000 women were 18.1 (95% CI 12.72-25.75; <em>P</em> &lt; .001) and 74.48 (95% CI 49.41-112.27; <em>P</em> &lt; .001), respectively. The ORs for misdiagnosis and unnecessary biopsy rates of 10 of 100 people were 0.006 (95% CI 0.003-0.012; <em>P</em> &lt; .001). Preferences for screening intervals varied, with a higher preference for screening every 4 years (OR 2.77; 95% CI 1.73-4.43; <em>P</em> &lt; .001) compared with annual screening. The cost was also a significant factor, with a decrease in the odds of choosing a screening option as the cost increased (OR 0.139; 95% CI 0.1396-0.1399; <em>P</em> = .001).</div></div><div><h3>Conclusions</h3><div>This study provides valuable insights into women’s preferences for breast cancer screening in Iran.</div></div>","PeriodicalId":23497,"journal":{"name":"Value in health regional issues","volume":"48 ","pages":"Article 101110"},"PeriodicalIF":1.4,"publicationDate":"2025-03-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143681536","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Diabetes Mellitus in Colombia: Estimates of the Years of Life Lost","authors":"Pablo Chaparro-Narváez MD, PhD ,&nbsp;Diana Díaz-Jiménez BSHA, MSc ,&nbsp;Nelson J. Alvis-Zakzuk BEcon, MSc ,&nbsp;Carlos Castañeda-Orjuela MD, MSc, PhD","doi":"10.1016/j.vhri.2025.101100","DOIUrl":"10.1016/j.vhri.2025.101100","url":null,"abstract":"<div><h3>Objectives</h3><div>Accurate estimates of years of life lost (YLLs) are necessary to assess the management of diabetes mellitus (DM) and to understand the burden of the disease on society. We aimed to quantify the impact of mortality because of DM by estimating the YLLs in Colombia between 1979 and 2017.</div></div><div><h3>Methods</h3><div>An ecological study was conducted using mortality data from the National Administrative Department of Statistics of Colombia. YLLs attributable to DM and trends in the rates of YLLs by sex and age group were estimated using Joinpoint Regression. Forecasts of YLLs because of DM were performed using autoregressive integrated moving average models.</div></div><div><h3>Results</h3><div>Between 1979 and 2017, 200 650 deaths were registered, whose basic cause of death was DM. Up to 69 years of age, it was observed for both sexes that the older the age group, the higher the proportion of YLLs. The trend of the adjusted rate of the YLLs estimated for DM increased between 1979 and 2000 to 2001 and later decreased more sharply among women, and the reduction was high for the 65 and over age groups. The 2018 to 2025 YLL rates for DM in Colombia are predicted to have the highest values in the total series in April 2024 (13 514/1000 population).</div></div><div><h3>Conclusions</h3><div>In Colombia, between 1979 and 2017, the YLLs and age-adjusted rates of YLLs because of DM showed a slight decrease in both men and women.</div></div>","PeriodicalId":23497,"journal":{"name":"Value in health regional issues","volume":"48 ","pages":"Article 101100"},"PeriodicalIF":1.4,"publicationDate":"2025-03-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143628105","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}